US 12,274,714 B2
Early apoptotic cells for use treating sepsis
Shai Novik, Ramat Hasharon (IL); and Dror Mevorach, Jerusalem (IL)
Assigned to ENLIVEX THERAPEUTICS R&D LTD, Nes-Ziona (IL)
Filed by Enlivex Therapeutics Ltd., Nes-Ziona (IL)
Filed on Jan. 4, 2022, as Appl. No. 17/567,923.
Application 17/567,923 is a continuation of application No. 16/194,417, filed on Nov. 19, 2018, granted, now 11,304,976.
Application 16/194,417 is a continuation in part of application No. 15/685,086, filed on Aug. 24, 2017, granted, now 11,000,548.
Application 15/685,086 is a continuation in part of application No. 15/551,284, granted, now 11,512,289, previously published as PCT/IL2016/050194, filed on Feb. 18, 2016.
Application 15/685,086 is a continuation in part of application No. PCT/IL2017/050196, filed on Feb. 15, 2017.
Application 15/685,086 is a continuation in part of application No. PCT/IL2016/050430, filed on Apr. 21, 2016.
Claims priority of provisional application 62/117,752, filed on Feb. 18, 2015.
Claims priority of provisional application 62/127,218, filed on Mar. 2, 2015.
Claims priority of provisional application 62/148,227, filed on Apr. 16, 2015.
Claims priority of provisional application 62/159,365, filed on May 11, 2015.
Claims priority of provisional application 62/296,622, filed on Feb. 18, 2016.
Claims priority of provisional application 62/370,741, filed on Aug. 4, 2016.
Claims priority of provisional application 62/150,305, filed on Apr. 21, 2015.
Claims priority of provisional application 62/516,714, filed on Jun. 8, 2017.
Prior Publication US 2022/0133799 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/12 (2015.01); A61K 39/00 (2006.01); A61P 31/04 (2006.01); A61K 9/00 (2006.01)
CPC A61K 35/12 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464419 (2023.05); A61P 31/04 (2018.01); A61K 9/0019 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/59 (2023.05)] 18 Claims
 
1. A method of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating sepsis, or any combination thereof, in a subject in need, comprising the step of administering a composition comprising a dose of early apoptotic cell population comprising 40-240×10 6 cells/kg to said subject, wherein said early apoptotic cells comprise peripheral blood mononuclear cells having ≥40% AnnexinV+ and ≤15% propidium iodide+, and wherein said administering treats, prevents, inhibits, reduces the incidence of, ameliorates, or alleviates sepsis in said subject.